| Literature DB >> 33832522 |
Charalampos Loutradis1,2, Luke Pickup3,4, Jonathan P Law5,3, Indranil Dasgupta5,4, Jonathan N Townend3,6, Paul Cockwell5, Adnan Sharif5, Pantelis Sarafidis7, Charles J Ferro5,3.
Abstract
BACKGROUND: The association of several comorbidities, including diabetes mellitus, hypertension, cardiovascular disease, heart failure and chronic kidney or liver disease, with acute kidney injury (AKI) is well established. Evidence on the effect of sex and socioeconomic factors are scarce. This study was designed to examine the association of sex and socioeconomic factors with AKI and AKI-related mortality and further to evaluate the additional relationship with other possible risk factors for AKI occurrence.Entities:
Keywords: Acute kidney injury; Alcohol; Mortality; Sex; Smoking; Social status
Mesh:
Year: 2021 PMID: 33832522 PMCID: PMC8034098 DOI: 10.1186/s13293-021-00373-4
Source DB: PubMed Journal: Biol Sex Differ ISSN: 2042-6410 Impact factor: 5.027
Fig. 1Patients’ enrolment and study flow diagram
Baseline characteristics in patients by sex and in the total population studied
| Parameter | Total population | Male | Female | |
|---|---|---|---|---|
| 3534 | 1878 | 1656 | - | |
| Age (years) | 60.7 ± 18.8 | 61.1 ± 17.8 | 60.3 ± 20.0 | 0.18 |
| Ethnicity | ||||
| White ( | 3016 (85.3) | 1589 (84.6) | 1427 (86.2) | 0.49 |
| Black ( | 103 (2.9) | 55 (2.9) | 48 (2.9) | |
| Asian ( | 338 (9.6) | 188 (10.0) | 150 (9.1) | |
| Other ( | 77 (2.2) | 46 (2.4) | 31 (1.9) | |
| Index of multiple deprivation | ||||
| 1 | 1571 (44.5%) | 815 (43.4%) | 756 (45.7%) | 0.15 |
| 2 | 703 (19.9%) | 366 (19.5%) | 337 (20.4%) | |
| 3 | 662 (18.7%) | 363 (19.3%) | 299 (18.1%) | |
| 4–5 | 268 (7.6%) | 157 (8.4%) | 111 (6.7%) | |
| Height (m) | 1.65 ± 0.12 | 1.71 ± 0.10 | 1.57 ± 0.10 | |
| Weight (kg) | 77.29 ± 20.74 | 81.77 ± 19.28 | 72.18 ± 21.16 | |
| BMI (kg/m2) | 27.16 [8.50] | 27.05 [7.50] | 27.39 [9.90] | |
| Diabetes ( | 677 (19.2) | 389 (20.7) | 288 (17.4) | |
| Hypertension ( | 1327 (37.5) | 751 (40.0) | 576 (34.8) | |
| Coronary Heart Disease ( | 430 (12.2) | 300 (16.0) | 130 (7.9) | |
| Stroke ( | 127 (3.6) | 63 (3.4) | 64 (3.9) | 0.42 |
| Peripheral Vascular Disease ( | 168 (4.8) | 120 (6.4) | 48 (2.9) | |
| Heart Failure ( | 318 (9.0) | 188 (10.0) | 130 (7.9) | |
| Renal Disease ( | 160 (4.5) | 92 (4.9) | 68 (4.1) | 0.25 |
| Liver Disease ( | 39 (1.1) | 24 (1.3) | 15 (0.9) | 0.29 |
| Pulmonary Disease ( | 860 (24.3) | 380 (20.2) | 480 (29.0) | |
| Malignancy ( | 440 (12.5) | 295 (15.7) | 145 (8.8) | |
| Charlson Comorbidity Index | 1.14 ± 1.50 | 1.22 ± 1.59 | 1.05 ± 1.37 | |
| Smoking | ||||
| Current | 921 (26.1%) | 520 (27.7%) | 401 (24.2%) | |
| Ex-smoker | 1286 (36.4%) | 777 (41.4%) | 509 (30.7%) | |
| Alcohol | ||||
| Moderate consumption ( | 779 (22.0) | 547 (29.1) | 232 (14.0) | |
| Higher consumption ( | 430 (12.2) | 312 (16.6) | 118 (7.1) | |
| Antihypertensive drugs ( | 1642 (46.5) | 914 (48.7) | 728 (44.0) | |
| ACEI ( | 698 (19.8) | 428 (22.8) | 270 (16.3) | |
| ARB ( | 285 (8.1) | 152 (8.1) | 133 (8.0) | 0.90 |
| CCB ( | 595 (16.8) | 344 (18.3) | 251 (15.2) | |
| Diuretics ( | 710 (20.1) | 341 (18.2) | 369 (22.3) | |
| Beta-blockers ( | 569 (16.1) | 353 (18.8) | 216 (13.0) | |
| Alpha1-blockers ( | 194 (5.5) | 149 (7.9) | 45 (2.7) | |
| Statins ( | 430 (12.2) | 249 (13.3) | 181 (10.9) | 0.06 |
| Non-steroidal anti-inflammatory drugs ( | 109 (3.1) | 54 (2.9) | 55 (3.3) | 0.47 |
| Proton-pump inhibitors or histamine H2-receptor antagonists ( | 943 (26.7) | 488 (26.0) | 455 (27.5) | 0.57 |
| Haloperidol ( | 78 (2.2) | 35 (1.9) | 43 (2.6) | 0.18 |
| e-GFR (ml/min/1.73m2) | 86.71 [36.59] | 86.20 [35.94] | 87.39 [37.32] | 0.08 |
| Creatinine (μmol/l) | 74.00 [31.00] | 83.00 [33.00] | 64.50 [24.00] | |
| Urea (mmol/l) | 6.90 [4.20] | 7.10 [4.00] | 6.50 [4.40] | |
| Sodium (mmol/l) | 138.00 [4.00] | 138.00 [4.00] | 138.00 [4.00] | 0.12 |
| Potassium (mmol/l) | 4.20 [0.60] | 4.30 [0.60] | 4.20 [0.60] | |
| Haemoglobin (g/l) | 125.00 [30.00] | 129.00 [31.00] | 120.00 [28.00] | |
| Anaemia ( | 1730 (49.0) | 937 (49.9) | 793 (47.9) | 0.267 |
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers, BMI, body mass index; CCB, calcium channel blockers; IMD, index of multiple deprivation
Normally distributed variables are presented as mean ± standard deviation, non-normally distributed variables as median (interquartile range) and categorical variables as absolute frequency (proportion)
Diagnosis of admission in patients by sex and in the total population studied
| Parameter | Total population | Male | Female | |
|---|---|---|---|---|
| 3534 | 1878 | 1656 | - | |
| Cardiology ( | 707 (20.0) | 446 (23.7) | 261 (15.8) | |
| Gastroenterology ( | 463 (13.1) | 213 (11.3) | 250 (15.1) | |
| Musculoskeletal/trauma ( | 407 (11.5) | 174 (9.3) | 233 (14.1) | |
| Malignancy ( | 275 (7.8) | 179 (9.5) | 96 (5.8) | |
| Neurology ( | 152 (4.3) | 57 (3.0) | 95 (5.7) | |
| Renal ( | 208 (5.9) | 148 (7.9) | 60 (3.6) | |
| Respiratory ( | 279 (7.9) | 134 (7.1) | 145 (8.8) | |
| Infection ( | 630 (17.8) | 338 (18.0) | 292 (17.6) | |
| Other ( | 294 (8.3) | 124 (6.6) | 170 (10.3) | |
| Not Specified ( | 119 (3.4) | 65 (3.5) | 54 (3.3) |
Stepwise logistic regression modelled analysis for the association of male sex with acute kidney injury
| Risk of AKI | Patients included in the model | ||
|---|---|---|---|
| OR (95% CI) | |||
| 1.659 (1.311–2.099) | 3534 | ||
| 1.670 (1.317–2.117) | 3534 | ||
| 1.640 (1.292–2.081) | 3534 | ||
| 1.628 (1.274–2.081) | 3204 | ||
| 1.573 (1.207–2.049) | 2290 | ||
| 1.599 (1.215–2.103) | 2060 | ||
AKI, acute kidney injury; BMI, body mass index; CI, confidence intervals; eGFR, estimated glomerular filtration rate; HR, hazard ratio; OR, odds ratio; Model 1, unadjusted; Model 2, adjusted for age; Model 3, adjusted for age and eGFR; Model 4, adjusted for age, eGFR, indices of deprivation, smoking, alcohol consumption and race; Model 5, adjusted for age, eGFR, indices of deprivation, smoking, alcohol consumption, race, BMI, diabetes, hypertension, coronary heart disease, stroke, peripheral vascular disease, heart failure, renal disease, liver disease, pulmonary disease and malignancy; Model 6, adjusted for age, eGFR, indices of deprivation, smoking, alcohol consumption, race, BMI, diabetes, hypertension, coronary heart disease, stroke, peripheral vascular disease, heart failure, renal disease, liver disease, pulmonary disease, malignancy, antihypertensive medication intake, statin intake, sodium, potassium and haemoglobin levels
Comparisons of 30-day, 6-month, 1-year and 48-month all-cause mortality in male and female patients with and without AKI
| Parameter | Male | Female | |||||
|---|---|---|---|---|---|---|---|
| Without AKI | With AKI | Without AKI | With AKI | - | |||
| 1666 | 212 | - | 1538 | 118 | - | - | |
| All-cause mortality in 30 days ( | 30 (1.8%) | 9 (4.2%) | 12 (0.8%) | 8 (6.8%) | 0.318 | ||
| All-cause mortality in 6 months ( | 107 (6.4%) | 42 (19.8%) | 89 (5.8%) | 18 (15.3%) | 0.304 | ||
| All-cause mortality in 1 year ( | 186 (11.2%) | 56 (26.4%) | 137 (8.9%) | 25 (21.2%) | 0.350 | ||
| All-cause mortality in 48 months ( | 364 (21.8%) | 83 (39.2%) | 318 (20.7%) | 56 (47.5%) | 0.163 | ||
#Comparison between patients with and without AKI
*Comparison between male and female patients with AKI
AKI, acute kidney injury
Fig. 2Kaplan-Meier curves in male and female patients with and without AKI during the a 30-day, b 6-month, c 1-year, and d 48-month follow-up periods
Stepwise Cox regression modelled analysis for the association of male sex with all-cause mortality after acute kidney injury occurrence during the 30-day and the 6-month follow-up periods in the total studied population
| 30-day all-cause mortality after AKI | 6-month all-cause mortality after AKI | 1-year all-cause mortality after AKI | 48-month all-cause mortality after AKI | Patients included in the model | |||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||||
| 0.996, 0.384–2.582 | 0.99 | 2.083, 0.199–3.619 | 2.007, 1.252–3.216 | 1.334, 0.950–1.872 | 0.10 | 3534 | |||
| 1.005, 0.387–2.606 | 0.99 | 2.159, 1.241–3.754 | 2.120, 1.321–3.402 | 1.442, 1.026–2.028 | 3534 | ||||
| 0.957, 0.369–2.482 | 0.93 | 2.003, 1.153–3.480 | 1.994, 1.243–3.200 | 1.351, 0.961–1.899 | 0.08 | 3534 | |||
| 0.820, 0.307–2.194 | 0.69 | 1.996, 1.147–3.474 | 2.029, 1.250–3.293 | 1.257, 0.882–1.792 | 0.21 | 3204 | |||
| 0.697, 0.242–2.006 | 0.50 | 1.521, 0.817–2.829 | 0.19 | 1.400, 0.821–2.389 | 0.22 | 0.978, 0.652–1.468 | 0.92 | 2290 | |
| 0.456, 0.151–1.376 | 0.16 | 1.405, 0.747–2.642 | 0.29 | 1.442, 0.806–2.578 | 0.22 | 1.032, 0.676–1.575 | 0.88 | 2060 | |
AKI, acute kidney injury; BMI, body mass index; CI, confidence intervals; eGFR, estimated glomerular filtration rate; HR, hazard ratio; OR, odds ratio; Model 1, unadjusted; Model 2, adjusted for age; Model 3, adjusted for age and eGFR; Model 4, adjusted for age, eGFR, indices of deprivation, smoking, alcohol consumption and ethnicity; Model 5, adjusted for age, eGFR, indices of deprivation, smoking, alcohol consumption, ethnicity, BMI, diabetes, hypertension, coronary heart disease, stroke, peripheral vascular disease, heart failure, renal disease, liver disease, pulmonary disease and malignancy; Model 6, adjusted for age, eGFR, indices of deprivation, smoking, alcohol consumption, ethnicity, BMI, diabetes, hypertension, coronary heart disease, stroke, peripheral vascular disease, heart failure, renal disease, liver disease, pulmonary disease, malignancy, antihypertensive medication intake, statin intake, sodium, potassium and haemoglobin levels